<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21783" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>First-Pass Effect</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Herman</surname>
            <given-names>Timothy F.</given-names>
          </name>
          <aff>University of Tennessee HSC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Santos</surname>
            <given-names>Cynthia</given-names>
          </name>
          <aff>Rutgers New Jersey Medical School</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Timothy Herman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Cynthia Santos declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21783.s1" sec-type="Definition/Introduction">
        <title>Definition/Introduction</title>
        <p content-type="pubmed-excerpt">The first-pass effect is a pharmacological phenomenon in which a medication undergoes metabolism at a specific location in the body. The first-pass effect decreases the active drug's concentration upon reaching systemic circulation or its site of action. The first-pass effect is often associated with the liver, a major site of drug metabolism. However, the first-pass effect can also occur in the body's lungs, vasculature, gastrointestinal tract, and other metabolically active tissues. This effect can be increased by various factors such as plasma protein concentrations, gastrointestinal motility, and enzymatic activity.<xref ref-type="bibr" rid="article-21783.r1">[1]</xref><xref ref-type="bibr" rid="article-21783.r2">[2]</xref><xref ref-type="bibr" rid="article-21783.r3">[3]</xref>&#x000a0;The extent to which a patient may undergo the first-pass effect differs from patient to patient, and this must also be considered when determining appropriate dosing.<xref ref-type="bibr" rid="article-21783.r4">[4]</xref><xref ref-type="bibr" rid="article-21783.r5">[5]</xref>&#x000a0;If the first-pass effect is significantly prominent in a patient, the medication may require administration via a different route or formulation to bypass the first-pass effect.<xref ref-type="bibr" rid="article-21783.r6">[6]</xref></p>
      </sec>
      <sec id="article-21783.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>A significant issue of concern with the first-pass effect is considering its variability among different individual patients. It is essential that pharmacological dosing considers these natural variations in human metabolism to ensure patients remain within the therapeutic window of the appropriate drug.<xref ref-type="bibr" rid="article-21783.r4">[4]</xref>&#x000a0;Also, differences in the first-pass effect have been noted based on gender and age.<xref ref-type="bibr" rid="article-21783.r7">[7]</xref><xref ref-type="bibr" rid="article-21783.r8">[8]</xref></p>
      </sec>
      <sec id="article-21783.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The clinical significance of the first-pass effect is crucial to the proper administration and maintenance of pharmacological therapy. Some drugs that undergo considerable first-pass metabolism include alprenolol, 5-fluorouracil, morphine, pentazocine, and mercaptopurine. When given orally, these drugs are quickly metabolized via the first-pass effect, requiring their oral dosages to be much larger than their intravenous dosages. The first-pass effect also impacts peak drug concentrations, which may result in drug concentration peaks occurring much earlier than they would in a parenteral dose.<xref ref-type="bibr" rid="article-21783.r5">[5]</xref><xref ref-type="bibr" rid="article-21783.r9">[9]</xref></p>
        <p>Sublingual nitroglycerin quickly relieves symptoms of angina due to its high lipid solubility and bypassing the first-pass effect before entering the systemic circulation.<xref ref-type="bibr" rid="article-21783.r10">[10]</xref>&#x000a0;Isosorbide mononitrate differs from nitroglycerin. ISMN undergoes minimal first-pass metabolism, leading to high bioavailability after oral administration. However, its onset of action is too slow for the acute treatment of angina.<xref ref-type="bibr" rid="article-21783.r11">[11]</xref>&#x000a0;Administering diazepam rectally in children with febrile seizures significantly bypasses first-pass metabolism, ensuring a rapid onset of anticonvulsant effects, which is particularly important in prehospital settings.<xref ref-type="bibr" rid="article-21783.r12">[12]</xref><xref ref-type="bibr" rid="article-21783.r13">[13]</xref>&#x000a0;</p>
        <p>Research has shown that monitoring blood concentrations of drugs that experience the first-pass effect is the most viable way to maintain therapeutic concentrations of these drugs.<xref ref-type="bibr" rid="article-21783.r14">[14]</xref>&#x000a0;Dextromethorphan, acting as a substrate for CYP2D6 and undergoing significant first-pass bioinactivation, exhibits potential in treating the pseudobulbar-affect. The co-administration of dextromethorphan with a minimal dose of quinidine effectively inhibits first-pass metabolism, resulting in increased systemic concentrations compared to monotherapy. This combination therapy is now FDA-approved for managing the pseudobulbar-affect.<xref ref-type="bibr" rid="article-21783.r15">[15]</xref></p>
      </sec>
      <sec id="article-21783.s4" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>The interprofessional healthcare team (eg, physicians, advanced practitioners, nurses, and pharmacists) must work together to ensure the safety and efficacy of pharmacotherapy. The healthcare team should monitor for signs of adverse drug reactions. The pharmacist should verify the dosing, perform medication reconciliation, and perform a drug interaction check.<xref ref-type="bibr" rid="article-21783.r16">[16]</xref>&#x000a0;Nurses can monitor adverse events and assess treatment effectiveness on subsequent visits. Applying basic pharmacokinetic concepts, eg, the first pass effect, can ensure the appropriate drug route of administration and dosing of the patient. Open communication&#x000a0;among nurses, pharmacists, and the prescribing physician is crucial for reporting and discussing any concerns regarding pharmacotherapy. An interprofessional team approach with open communication is essential to optimize patient outcomes with minimal adverse events.</p>
      </sec>
      <sec id="article-21783.s5" sec-type="Nursing, Allied Health, and Interprofessional Team Monitoring">
        <title>Nursing, Allied Health, and Interprofessional Team Monitoring</title>
        <p>When monitoring patients taking drugs that experience the first-pass effect, it is critical to monitor the blood concentrations of these drugs to ensure that the patient's serum drug concentrations remain within their therapeutic windows. Implementing this approach will optimize the effectiveness of the treatment and enhance patient safety.<xref ref-type="bibr" rid="article-21783.r14">[14]</xref></p>
      </sec>
      <sec id="article-21783.s6">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21783&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21783">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21783/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21783">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21783.s7">
        <title>References</title>
        <ref id="article-21783.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doherty</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>First-pass effect: significance of the intestine for absorption and metabolism.</article-title>
            <source>Drug Chem Toxicol</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>329</fpage>
            <page-range>329-44</page-range>
            <pub-id pub-id-type="pmid">9433662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qiao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats.</article-title>
            <source>J Ethnopharmacol</source>
            <year>2017</year>
            <month>Sep</month>
            <day>14</day>
            <volume>209</volume>
            <fpage>175</fpage>
            <page-range>175-183</page-range>
            <pub-id pub-id-type="pmid">28755970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Kunze</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Thummel</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction.</article-title>
            <source>Adv Drug Deliv Rev</source>
            <year>1997</year>
            <month>Sep</month>
            <day>15</day>
            <volume>27</volume>
            <issue>2-3</issue>
            <fpage>99</fpage>
            <page-range>99-127</page-range>
            <pub-id pub-id-type="pmid">10837554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tam</surname>
                <given-names>YK</given-names>
              </name>
            </person-group>
            <article-title>Individual variation in first-pass metabolism.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>300</fpage>
            <page-range>300-28</page-range>
            <pub-id pub-id-type="pmid">8261714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pond</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Tozer</surname>
                <given-names>TN</given-names>
              </name>
            </person-group>
            <article-title>First-pass elimination. Basic concepts and clinical consequences.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1984</year>
            <season>Jan-Feb</season>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-25</page-range>
            <pub-id pub-id-type="pmid">6362950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mattes</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Edling-Owens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Engelman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Elsohly</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Bypassing the first-pass effect for the therapeutic use of cannabinoids.</article-title>
            <source>Pharmacol Biochem Behav</source>
            <year>1993</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>745</fpage>
            <page-range>745-7</page-range>
            <pub-id pub-id-type="pmid">8383856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baraona</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abittan</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Dohmen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moretti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pozzato</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chayes</surname>
                <given-names>ZW</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lieber</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Gender differences in pharmacokinetics of alcohol.</article-title>
            <source>Alcohol Clin Exp Res</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>502</fpage>
            <page-range>502-7</page-range>
            <pub-id pub-id-type="pmid">11329488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wynne</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Drug metabolism and ageing.</article-title>
            <source>J Br Menopause Soc</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>51</fpage>
            <page-range>51-6</page-range>
            <pub-id pub-id-type="pmid">15970015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lalka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Cronenberger</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>The hepatic first-pass metabolism of problematic drugs.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1993</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>657</fpage>
            <page-range>657-69</page-range>
            <pub-id pub-id-type="pmid">8366191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Divakaran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Loscalzo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Nov</month>
            <day>07</day>
            <volume>70</volume>
            <issue>19</issue>
            <fpage>2393</fpage>
            <page-range>2393-2410</page-range>
            <pub-id pub-id-type="pmid">29096811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <chapter-title>Organic Nitrates</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>4</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">31643263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shinnar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alldredge</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bainbridge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bare</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dodson</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Garrity</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jagoda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pellock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riviello</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Treiman</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.</article-title>
            <source>Epilepsy Curr</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-61</page-range>
            <pub-id pub-id-type="pmid">26900382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eilbert</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Febrile seizures: A review.</article-title>
            <source>J Am Coll Emerg Physicians Open</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>e12769</fpage>
            <pub-id pub-id-type="pmid">36016968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wargin</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Sawchuk</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>McCoy</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Rylander</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Variable first-pass elimination of propranolol following single and multiple oral doses in hypertensive patients.</article-title>
            <source>Eur J Drug Metab Pharmacokinet</source>
            <year>1982</year>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>183</fpage>
            <page-range>183-9</page-range>
            <pub-id pub-id-type="pmid">7173272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fralick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sacks</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kesselheim</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.</article-title>
            <source>JAMA Intern Med</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>179</volume>
            <issue>2</issue>
            <fpage>224</fpage>
            <page-range>224-230</page-range>
            <pub-id pub-id-type="pmid">30615021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21783.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Splawski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Minger</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Value of the Pharmacist in the Medication Reconciliation Process.</article-title>
            <source>P T</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>176</fpage>
            <page-range>176-8</page-range>
            <pub-id pub-id-type="pmid">26957885</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
